Mix Vaccine for Metastatic Colorectal Cancer
The aim of this study is the safety and efficacy of mix vaccine to small metastases of colorectal cancer.
Metastatic Colorectal Cancer|Reaction - Mixed Vaccine
BIOLOGICAL: Mix vaccine
Relief degree of tumors, It will be evaluated by the Response Evaluation Criteria in Solid Tumors（RECIST）, 3 months
Progress free survival（PFS）, The duration from the beginning of treatment to cancer recurrence or progression, 1 year|Overall survival（OS）, The duration from the beginning of treatment to patient death, 3 years
By enrolling patients with small metastases of colorectal cancer adapted to enrolled criteria, this study will document for the first time the safety and the short and long term efficacy of mix vaccine.

The safety will be evaluated by statistics of adverse reactions. The efficacy will be evaluated according to local relief degree, progress free survival (PFS) and overall survival (OS).